Medical Devices & Surgical Technology Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Devices & Surgical Technology Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Heart Failure
St. Jude Medical Announces FDA and CE Mark Approvals of QuickOpt Timing Cycle Optimization for Additional Heart Failure Devices
July 22nd, 2007
St. Jude Medical, Inc. (NYSE:STJ) announced U.S. Food and Drug Administration (FDA) and European CE Mark approvals to expand the capabilities of its Frontier(R) II cardiac resynchronization therapy pacemaker (CRT-P) to include QuickOpt(TM) Timing Cycle Optimization, giving physicians a new option to manage therapy for patients based on their individual needs. The Frontier II device is the first heart failure pacemaker with QuickOpt Timing Cycle Optimization. In about 90 seconds, the QuickOpt feature recommends to physicians which A-V (atrial-ventricular) and V-V (ventricular-ventricular) timing values to use to program the devices. This allows physicians to frequently...
Source: Medical Devices & Surgical Technology Week (2007-07-22)
|
